Approved comparison material connected to this topic.
6 total recordsSource comparisons are presented without a generated winner.
Dosage 2–2.5mg per injection 2mg per injection Using <1.5mg (insufficient VEGF upregulation) Frequency Twice weekly (every 3–4 days) Once weekly Daily microdosing (disrupts stable plasma levels) Injection Timi…
Primary Action Actin sequestration in follicle stem cells; Wnt/β-catenin pathway activation ATP-sensitive potassium channel opening; increased cutaneous blood flow 5-alpha reductase Type II inhibition; reduced…
Murine dermal wound healing C57BL/6 mice (n=24) Re-epithelialization rate at day 7 85% closure (TB-500) vs 58% (control) Demonstrates wound repair efficacy. Not follicular cycling Rat whisker follicle regrowth…
No randomized controlled trial has evaluated TB-500 for androgenetic alopecia in humans as of 2026. The evidence base consists of: (1) in vitro studies showing VEGF upregulation in dermal papilla cells, (2) eq…
Tissue Repair Standard 5–10mg 2×/week (loading), 2–5mg weekly (maintenance) 8–12 weeks loading, 12+ weeks maintenance Subcutaneous injection Systemic tissue repair support, follicular angiogenesis as secondary…
Week 0–2 VEGF upregulation begins; actin binding in dermal papilla cells None. May notice increased shedding Baseline photo documentation recommended Early shedding indicates follicle phase transition. Continu…